trial

Creatine Treatment in Psychiatric Disorders

NCTId NCT00140192
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 12 (actual)
Sponsored by Beersheva Mental Health Center
Primary completion 2006-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
12 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2004-09
Primary completion
2006-03
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
creatine

Sponsors

Beersheva Mental Health CenterLead Sponsor
National Alliance for Research on Schizophrenia and DepressionCollaborator

Investigators

1
RH Belmaker, MDStudy Director

Sites

1 total
Beersheva, Israel

Linked catalysts

1
Creatine Treatment in Psychiatric Disorders — primary completion2006-03

Facts & assertions

4 sourced
Enrollment
12
Phase
PHASE3
Primary Completion Date
2006-03
Status
COMPLETED
relationships
The graph out of here
drug
creatine
drug
lead_sponsor
Beersheva Mental Health Center
company
collaborator
National Alliance for Research on Schizophrenia and Depression
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
RH Belmaker, MD
person